Bruker Co. (NASDAQ:BRKR) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC reduced its position in shares of Bruker Co. (NASDAQ:BRKR) by 12.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 73,578 shares of the medical research company’s stock after selling 10,718 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Bruker were worth $5,407,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BRKR. First Republic Investment Management Inc. boosted its position in shares of Bruker by 0.7% during the 4th quarter. First Republic Investment Management Inc. now owns 21,414 shares of the medical research company’s stock valued at $1,464,000 after purchasing an additional 150 shares in the last quarter. Baker Tilly Wealth Management LLC boosted its holdings in Bruker by 3.0% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 5,285 shares of the medical research company’s stock worth $388,000 after buying an additional 156 shares in the last quarter. IFP Advisors Inc grew its position in Bruker by 67.8% in the second quarter. IFP Advisors Inc now owns 438 shares of the medical research company’s stock worth $32,000 after buying an additional 177 shares during the last quarter. Legacy Wealth Asset Management LLC increased its holdings in shares of Bruker by 5.7% in the fourth quarter. Legacy Wealth Asset Management LLC now owns 3,412 shares of the medical research company’s stock valued at $251,000 after buying an additional 184 shares in the last quarter. Finally, Fifth Third Bancorp increased its holdings in shares of Bruker by 53.3% in the third quarter. Fifth Third Bancorp now owns 541 shares of the medical research company’s stock valued at $34,000 after buying an additional 188 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on BRKR shares. Citigroup lifted their target price on Bruker from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. JPMorgan Chase & Co. upgraded Bruker from a “neutral” rating to an “overweight” rating and increased their price target for the company from $60.00 to $90.00 in a research report on Wednesday, February 14th. UBS Group boosted their price objective on Bruker from $94.00 to $102.00 and gave the stock a “buy” rating in a report on Friday, March 1st. The Goldman Sachs Group raised their target price on shares of Bruker from $66.00 to $74.00 and gave the stock a “sell” rating in a report on Wednesday, April 10th. Finally, Stifel Nicolaus boosted their price target on shares of Bruker from $63.00 to $81.00 and gave the company a “hold” rating in a report on Wednesday, February 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Bruker currently has a consensus rating of “Moderate Buy” and an average target price of $84.86.

Bruker Trading Down 5.3 %

Shares of NASDAQ BRKR opened at $78.56 on Friday. The company has a current ratio of 1.80, a quick ratio of 0.99 and a debt-to-equity ratio of 0.83. Bruker Co. has a one year low of $53.79 and a one year high of $94.86. The business has a 50-day moving average price of $87.64 and a two-hundred day moving average price of $73.86. The firm has a market capitalization of $10.82 billion, a PE ratio of 26.90, a PEG ratio of 2.13 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, February 13th. The medical research company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. The business had revenue of $844.50 million during the quarter, compared to analysts’ expectations of $809.35 million. Bruker had a net margin of 14.41% and a return on equity of 29.94%. The firm’s quarterly revenue was up 19.2% compared to the same quarter last year. During the same period last year, the company posted $0.74 earnings per share. As a group, analysts predict that Bruker Co. will post 2.74 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Friday, March 1st were paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.25%. The ex-dividend date of this dividend was Thursday, February 29th. Bruker’s dividend payout ratio (DPR) is presently 6.85%.

Insider Buying and Selling

In other Bruker news, Director Hermann Fritz Requardt sold 15,000 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $90.06, for a total value of $1,350,900.00. Following the transaction, the director now owns 23,147 shares in the company, valued at $2,084,618.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 28.20% of the stock is owned by corporate insiders.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.